Daniel J. Brennan

October 6, 2026

Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.

October 17, 2026

Waters Launches AI Link for LC-MS Workflows. Waters Corporation introduced AI Link, a tool designed to advance AI-enabled LC-MS workflows from research to release. This product launch highlights the company's focus on integrating artificial intelligence into its laboratory solutions. Additionally, TD Cowen raised its price target to $515, reflecting continued analyst interest in the stock's potential.

October 17, 2026

Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.